BRPI0407264A - Inibidor de proteìna resistente ao câncer de mama (bcrp) - Google Patents
Inibidor de proteìna resistente ao câncer de mama (bcrp)Info
- Publication number
- BRPI0407264A BRPI0407264A BR0407264-2A BRPI0407264A BRPI0407264A BR PI0407264 A BRPI0407264 A BR PI0407264A BR PI0407264 A BRPI0407264 A BR PI0407264A BR PI0407264 A BRPI0407264 A BR PI0407264A
- Authority
- BR
- Brazil
- Prior art keywords
- salt
- glycopyranosyl
- alkoxy
- alkyl
- breast cancer
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 3
- 229940121649 protein inhibitor Drugs 0.000 title abstract 3
- 239000012268 protein inhibitor Substances 0.000 title abstract 3
- -1 hydroxy, nitro, amino, acetylamino Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- VFOKYTYWXOYPOX-RVDMUPIBSA-N (z)-2,3-diphenylprop-2-enenitrile Chemical class C=1C=CC=CC=1C(/C#N)=C/C1=CC=CC=C1 VFOKYTYWXOYPOX-RVDMUPIBSA-N 0.000 abstract 1
- QAQHAGQKCVWGNC-NTEUORMPSA-N (z)-2-(3,4-dimethoxyphenyl)-3-(4-hydroxyphenyl)prop-2-enenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(\C#N)=C\C1=CC=C(O)C=C1 QAQHAGQKCVWGNC-NTEUORMPSA-N 0.000 abstract 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910021653 sulphate ion Inorganic materials 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
"INIBIDOR DE PROTEìNA RESISTENTE AO CâNCER DE MAMA (BCRP)". Droga que inibe BCRPS. Trata-se de um inibidor de proteína resistente o câncer de mama, que contém como um ingrediente ativo, ou um derivado difenilacrilonitrila representado pela seguinte fórmula (1); (1) (em que cada um dos 8 Rls, são iguais ou diferentes entre si, e representam independentemente, hidrogênio, hidróxi, nitro, amino, acetilamino, -NHCOCH3), ciano (-CN), formila (-CHO), -COOR~ 1 (R~ 1~ é hidrogênio OU C~ 1-4~ alquila), -O(CH~ 2~) ~ N~COOR~ 2~ (n = 1-7 e R~ 2~ é hidrogênio OU C~ 1-4~ alquila), -OOCCH2CH~ 2~COOR~ 3~ (R~ 3~ é hidrogênio, C~ 1-4~ alquila, (Z)-2-(3,4-dimetóxi-fenil)-3-(4-hidróxi-fenil)acrilonitrila, ou glicopiranosila) , C~ 1-8~ alcóxi, C~ 1-4~ alquila, halogênio, ((C~ 1-4~ alcóxi)C~ 1-4~ alcóxi)C~ 1-4~ alcóxi, C~ 2-8~ acilóxi, C~ 2-8~ halogeno-acilóxi, metileno-dióxi, trifluormetila, fosfato (-OP(O) (OH)~ 2~), ou um sal deste, grupo sulfato, (-OSO~ 3~H) ou um sal deste, glicopiranosila, ou um sal deste, fosfato de glicopiranosila ou um sal do éster, sulfato de glicopiranosila ou um sal do éster, ou piperidinopiperidinocarbonilóxi) ou um éster ou sal do derivado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003026856 | 2003-02-04 | ||
| PCT/JP2004/001067 WO2004069243A1 (ja) | 2003-02-04 | 2004-02-03 | 乳癌耐性蛋白（ｂｃｒｐ）阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0407264A true BRPI0407264A (pt) | 2006-01-31 |
Family
ID=32844154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0407264-2A BRPI0407264A (pt) | 2003-02-04 | 2004-02-03 | Inibidor de proteìna resistente ao câncer de mama (bcrp) |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7371773B2 (pt) |
| EP (1) | EP1591117A4 (pt) |
| JP (1) | JPWO2004069243A1 (pt) |
| KR (1) | KR20050096954A (pt) |
| CN (1) | CN1744892A (pt) |
| AU (1) | AU2004210259B2 (pt) |
| BR (1) | BRPI0407264A (pt) |
| CA (1) | CA2515174A1 (pt) |
| EA (1) | EA009048B1 (pt) |
| IL (1) | IL169913A0 (pt) |
| MX (1) | MXPA05008298A (pt) |
| NO (1) | NO20053956L (pt) |
| PL (1) | PL378073A1 (pt) |
| TW (1) | TW200505433A (pt) |
| WO (1) | WO2004069243A1 (pt) |
| ZA (1) | ZA200505988B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2433417C (en) * | 2001-01-18 | 2010-10-19 | Welichem Biotech Inc. | Novel 1,2-diphenylethene derivatives for treatment of immune diseases |
| BRPI0407264A (pt) | 2003-02-04 | 2006-01-31 | Yakult Honsha Kk | Inibidor de proteìna resistente ao câncer de mama (bcrp) |
| US7282339B2 (en) * | 2003-09-17 | 2007-10-16 | Invitrogen Corporation | Competitive immunoassay |
| AU2006232435B8 (en) * | 2005-03-30 | 2011-09-15 | Kabushiki Kaisha Yakult Honsha | BCRP/ABCG2 inhibitor |
| KR20100100826A (ko) | 2007-12-03 | 2010-09-15 | 가부시끼가이샤 야구르트혼샤 | Ａｂｃｇ2 저해제 |
| US8802702B2 (en) * | 2009-01-15 | 2014-08-12 | The General Hospital Corporation | Compounds for reducing drug resistance and uses thereof |
| FR2941456B1 (fr) * | 2009-01-26 | 2011-03-04 | Univ Claude Bernard Lyon | Nouveaux composes de type azapeptide ou azapeptidomimetrique inhibiteurs de bcrp et/ou p-gp. |
| US9168297B2 (en) | 2010-06-23 | 2015-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulation of skin pigmentation by neuregulin-1 (NRG-1) |
| CN105503652B (zh) * | 2015-12-30 | 2017-12-05 | 延边大学 | 含氰基白藜芦醇类似物及其制备方法和用途 |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| CN115768415A (zh) | 2020-04-22 | 2023-03-07 | 日本纽翱医药股份有限公司 | 新型冠状病毒感染症(covid-19)的治疗和/或预防剂 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3151148A (en) | 1964-09-29 | Cyano stilbene hypocholesterolemic | ||
| JP2799101B2 (ja) * | 1992-03-04 | 1998-09-17 | シャープ株式会社 | 有機非線形光学材料 |
| GB9207437D0 (en) * | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
| JP3144662B2 (ja) * | 1993-08-05 | 2001-03-12 | 森永乳業株式会社 | スチルベン誘導体とスチルベン同族体誘導体及びそれらの用途 |
| JP3180127B2 (ja) * | 1993-03-10 | 2001-06-25 | 森永乳業株式会社 | スチルベン誘導体とスチルベン同族体誘導体及びそれらの用途 |
| WO1994020456A1 (fr) | 1993-03-10 | 1994-09-15 | Morinaga Milk Industry Co., Ltd. | Derive de stilbene et derive d'analogue de stilbene, et utilisation de ces derives |
| TW325458B (en) * | 1993-09-08 | 1998-01-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer |
| US5731353A (en) * | 1993-09-08 | 1998-03-24 | Ajinomoto Co., Inc. | Stilbene derivatives and pharmaceutical compositions containing them |
| US5681835A (en) * | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| TW334418B (en) * | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| JP3163391B2 (ja) * | 1995-03-07 | 2001-05-08 | 味の素株式会社 | スチルベン誘導体及びそれを含有する制癌剤 |
| DE69918950T2 (de) * | 1998-02-06 | 2005-07-28 | De Montfort University | Durch hydroxylierung aktivierte medikamentvorstufen |
| IL138723A (en) * | 1998-04-03 | 2005-11-20 | Ajinomoto Kk | Composition containing cisplatin and stilbene for treatment of tumors |
| AU764132B2 (en) * | 1999-01-08 | 2003-08-14 | Bristol-Myers Squibb Company | Prokaryotic system designed to monitor protease activity |
| BRPI0407264A (pt) | 2003-02-04 | 2006-01-31 | Yakult Honsha Kk | Inibidor de proteìna resistente ao câncer de mama (bcrp) |
-
2004
- 2004-02-03 BR BR0407264-2A patent/BRPI0407264A/pt not_active IP Right Cessation
- 2004-02-03 CN CNA2004800032473A patent/CN1744892A/zh active Pending
- 2004-02-03 EP EP04707629A patent/EP1591117A4/en not_active Withdrawn
- 2004-02-03 JP JP2005504836A patent/JPWO2004069243A1/ja active Pending
- 2004-02-03 CA CA002515174A patent/CA2515174A1/en not_active Abandoned
- 2004-02-03 MX MXPA05008298A patent/MXPA05008298A/es active IP Right Grant
- 2004-02-03 KR KR1020057013822A patent/KR20050096954A/ko not_active Ceased
- 2004-02-03 PL PL378073A patent/PL378073A1/pl not_active Application Discontinuation
- 2004-02-03 EA EA200501247A patent/EA009048B1/ru unknown
- 2004-02-03 AU AU2004210259A patent/AU2004210259B2/en not_active Ceased
- 2004-02-03 WO PCT/JP2004/001067 patent/WO2004069243A1/ja not_active Ceased
- 2004-02-03 US US10/544,064 patent/US7371773B2/en not_active Expired - Fee Related
- 2004-02-04 TW TW093102500A patent/TW200505433A/zh unknown
-
2005
- 2005-07-26 IL IL169913A patent/IL169913A0/en unknown
- 2005-07-26 ZA ZA200505988A patent/ZA200505988B/xx unknown
- 2005-08-25 NO NO20053956A patent/NO20053956L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004210259A1 (en) | 2004-08-19 |
| AU2004210259B2 (en) | 2008-12-11 |
| JPWO2004069243A1 (ja) | 2006-05-25 |
| KR20050096954A (ko) | 2005-10-06 |
| MXPA05008298A (es) | 2005-09-20 |
| CN1744892A (zh) | 2006-03-08 |
| ZA200505988B (en) | 2006-12-27 |
| WO2004069243A1 (ja) | 2004-08-19 |
| EP1591117A4 (en) | 2006-04-26 |
| EP1591117A1 (en) | 2005-11-02 |
| EA200501247A1 (ru) | 2006-02-24 |
| PL378073A1 (pl) | 2006-02-20 |
| IL169913A0 (en) | 2007-07-04 |
| EA009048B1 (ru) | 2007-10-26 |
| NO20053956D0 (no) | 2005-08-25 |
| TW200505433A (en) | 2005-02-16 |
| US7371773B2 (en) | 2008-05-13 |
| US20060128636A1 (en) | 2006-06-15 |
| NO20053956L (no) | 2005-10-26 |
| CA2515174A1 (en) | 2004-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0008763A (pt) | Derivados de piridopiranoazepinas, a preparação dos mesmos e a respectiva aplicação em terapêutica | |
| AR050045A1 (es) | Derivados de pirrolo[3,4-c]pirazol activos como inhibidores de quinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| BRPI0407264A (pt) | Inibidor de proteìna resistente ao câncer de mama (bcrp) | |
| DE60112974D1 (en) | Carbolinderivate | |
| BR0312729A (pt) | Novos derivados de indol-3-enxofre | |
| BR0009297A (pt) | Composto, processo para produzir o mesmo,composição farmacêutica, método paraantagonizar hormÈnio de liberação degonadotropina em um mamìfero, e, uso de umcomposto | |
| EP1631548A4 (en) | HEMMER OF ACT ACTIVITY | |
| ATE368044T1 (de) | Salze mit cyanoborat-anionen | |
| EP1622616A4 (en) | HEMMER OF ACT ACTIVITY | |
| UA93351C2 (uk) | Похідні фталазіну як інгібітори parp | |
| DE69926806D1 (de) | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren | |
| DE69926919D1 (de) | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren | |
| ATE359786T1 (de) | Camptothecin derivate | |
| DE60216233D1 (en) | Carbolinderivate | |
| DE60206198T2 (de) | Tetrahydrochinolinderivate als muscarinische agonisten | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| CY1110061T1 (el) | Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης | |
| MXPA02012076A (es) | Compuestos quimicos. | |
| ATE332903T1 (de) | Kondensierte pyridoindolderivate | |
| ITMI20021620A1 (it) | Composto ad ativita' antitumorale | |
| MXPA02012659A (es) | Derivados de pirazindiona condensados. | |
| BR0115501A (pt) | Processo quìmico e novos intermediários | |
| BRPI0516904A (pt) | processo para a preparação de um derivado de 2-etilaminopiridina e composto | |
| BR9912575A (pt) | Processo para a preparação de um composto, e, composto. | |
| BR0215067A (pt) | Piridoquinoxalinas antivirais |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |